B2M and melanoma: In dMMR/MSI colorectal cancer and melanoma, genomic alterations in antigen-presenting machinery, including loss of beta-2-microglobulin and human leukocyte antigen (HLA) genes, are associated with resistance to checkpoint blockade54–56.